ClinicalTrials.gg

Program

rufinamide

Also written as “Rufinamide”, “SYN111” and “Rufinamide (E2080)”.

Its studies are mostly in Lennox Gastaut Syndrome · Epilepsy · Generalized Anxiety Disorder, led by 3 companies.

Furthest: phase 3, since Jun 7, 20067 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai50 open or runningphase 3since Jun 7, 2006Jun 7, 2006none ahead
Acorda Therapeutics10 open or runningphase 2since Jan 7, 2008Jan 7, 2008none ahead
Daiichi Sankyo10 open or runningphase 1since Dec 13, 2024Dec 13, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 7, 2006First study: phase 3 study in EpilepsyNew to EisaiEisai · NCT00334958 · 356 enrolled · United States
  2. Mar 15, 2007Phase 3 study in EpilepsyEisai · NCT00448539 · 286 enrolled · United States
  3. Jan 7, 2008Acorda Therapeutics's first study: phase 2 study in Generalized Anxiety DisorderNew to Acorda TherapeuticsAcorda Therapeutics · NCT00595231 · 239 enrolled · United States
  4. Jun 14, 20102 phase 3 studies in Lennox Gastaut SyndromeEisai · NCT01151540, NCT01146951
  5. Jul 27, 2011Phase 3 study in Lennox Gastaut SyndromeEisai · NCT01405053 · 37 enrolled · United States, Canada, France and more
  6. Dec 13, 2024Daiichi Sankyo's first study: phase 1 study in Healthy SubjectsNew to Daiichi SankyoDaiichi Sankyo · NCT06740825 · 32 enrolled · United States

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06740825Healthy Subjects · United States1CompletedDaiichi SankyoDec 9, 202432
NCT01405053Lennox Gastaut Syndrome · United States, Canada, France and more3CompletedEisaiNov 2, 201537
NCT01151540Lennox Gastaut Syndrome · Japan3CompletedEisaiAug 201354
NCT01146951Lennox Gastaut Syndrome · Japan3CompletedEisaiAug 201166
NCT00595231Generalized Anxiety Disorder · United States2CompletedAcorda TherapeuticsOct 2008239
NCT00448539Epilepsy · United States3TerminatedEisaiMay 14, 2010286
NCT00334958Epilepsy · United States3CompletedEisaiMay 20, 2009356

How it is read

Names in the registry

  • “Rufinamide”, 5 entries
  • “SYN111”, 1 entry
  • “Rufinamide (E2080)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.